The French Competition Authority fines pharmaceutical company for disparaging competiting generics (Sanofi-Aventis)

The French Competition Authority has handed down a fine of EUR 40 million to the Sanofi-Aventis Laboratory for implementing a practice of driving out competition by disparaging generic versions of its flagship product Plavix® to healthcare professionals in order to favor sales of the original product and Sanofi-Aventis’ own generic version, Clopidrogel Winthrop®. A complaint and a request for interim measures was filed against Sanofi-Aventis’ communication strategy by Téva Santé, French subsidiary of the world’s number 1 generic medicine producer. The

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Vogel & Vogel (Paris)

Quotation

Joseph Vogel, The French Competition Authority fines pharmaceutical company for disparaging competiting generics (Sanofi-Aventis), 14 May 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 52523

Visites 290

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues